What is CLL Phase I/II ACP-196 Study?
Category: Others
The CLL Phase I/II ACP-196 Study is a clinical trial examining the safety and efficacy of a new Bruton tyrosine kinase (Btk) inhibitor. It is a multi-center, dose escalation study.
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Irritability | 1 | 0 |
- Major
- Moderate
- Slight
- None
- Can't tell
Last updated: